Co-Diagnostics Financing Cash Flow
The Net Financing Cash Flow of Co-Diagnostics (CODX) as of Nov 20, 2026 is 11.81 M USD. In the previous year, Net Financing Cash Flow was 103,914.00 USD — a change of 11,266.69% (higher).
Get this data via API
Financial Data API
Financing Cash Flow
11.81 MUSD
YoY
11,266.69%
Last updated:
The Co-Diagnostics Financing Cash Flow history
3 Years
10 Years
25 Years
Max
| YEAR | Financing Cash Flow | YoY |
|---|---|---|
| 11.81 MUSD | +11,266.69% | |
| 103,914.00USD | -107.62% | |
| -1.36 MUSD | -90.28% | |
| -14.03 MUSD | -3,215.91% | |
| 450,398.00USD | -97.72% | |
| 19.74 MUSD | +234.44% | |
| 5.90 MUSD | +214.65% | |
| 1.88 MUSD | -68.40% | |
| 5.94 MUSD | +159.30% | |
| 2.29 MUSD | +56.81% | |
| 1.46 MUSD | +26.41% | |
| 1.15 MUSD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Co-Diagnostics Stock analysis
Frequently Asked Questions about Co-Diagnostics stock
Net Financing Cash Flow of Co-Diagnostics is 11.81 M USD in 2025.
Net Financing Cash Flow of Co-Diagnostics changed from 103,914.00 USD to 11.81 M USD, representing a 11,266.69% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Net Financing Cash Flow Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.
Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.
Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Co-Diagnostics historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cash Flow — Co-Diagnostics
All Key Metrics — Co-Diagnostics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth